| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1050700804 |
| P356 | DOI | 10.1038/SJ.TPJ.6500356 |
| P698 | PubMed publication ID | 16415921 |
| P5875 | ResearchGate publication ID | 7356321 |
| P50 | author | Alain Hovnanian | Q37840231 |
| Christine Lonjou | Q56524858 | ||
| P2093 | author name string | L Thomas | |
| M Schumacher | |||
| M Mockenhaupt | |||
| E Graf | |||
| J-C Roujeau | |||
| N Borot | |||
| N Ledger | |||
| C de Toma | |||
| H LeLouet | |||
| RegiSCAR Group | |||
| P2860 | cites work | HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol | Q24555784 |
| Genetic variations in HLA-B region and hypersensitivity reactions to abacavir | Q28214097 | ||
| Medical genetics: a marker for Stevens-Johnson syndrome | Q28254047 | ||
| Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism | Q33797447 | ||
| Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? | Q33818189 | ||
| Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis | Q34057610 | ||
| Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis | Q34093134 | ||
| Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir | Q34117815 | ||
| Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. | Q34475335 | ||
| The three-dimensional structure of peptide-MHC complexes | Q40444937 | ||
| Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. | Q40493792 | ||
| MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation | Q40807437 | ||
| Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+ T cells from allergic individuals | Q43503900 | ||
| Induction of T-cell-mediated skin disease specific for antigen transgenically expressed in keratinocytes | Q57174480 | ||
| Genetic susceptibility to toxic epidermal necrolysis | Q68772432 | ||
| P433 | issue | 4 | |
| P921 | main subject | Stevens–Johnson syndrome | Q1053948 |
| P304 | page(s) | 265-268 | |
| P577 | publication date | 2006-01-17 | |
| P1433 | published in | The Pharmacogenomics Journal | Q10534704 |
| P1476 | title | A marker for Stevens-Johnson syndrome ...: ethnicity matters | |
| P478 | volume | 6 |
| Q93590943 | Q93590943 |
| Q64118851 | A Screening Test for in a Large United States Patient Cohort Identifies Broader Risk of Carbamazepine-Induced Adverse Events |
| Q37669205 | A case of mexiletine-induced hypersensitivity syndrome presenting as eosinophilic pneumonia |
| Q38085220 | A review of pharmacogenetics of adverse drug reactions in elderly people |
| Q34116637 | Absence of HLA-B*1502 and HLA-A*3101 alleles in 9 Korean patients with antiepileptic drug-induced skin rash: a preliminary study |
| Q36541832 | Antecedent Drug Exposure Aetiology and Management Protocols in Steven-Johnson Syndrome and Toxic Epidermal Necrolysis, A Hospital Based Prospective Study |
| Q46051781 | Association between CYP2B6 polymorphisms and Nevirapine-induced SJS/TEN: a pharmacogenetics study |
| Q54094996 | Association between HLA gene polymorphism and cutaneous adverse reactions caused by antiepileptic drugs. |
| Q42910293 | Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China |
| Q54364109 | Association between the HLA-B*15:02 allele and carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Han individuals of northeastern China. |
| Q45922634 | Association of HLA-B*1502 and *1511 allele with antiepileptic drug-induced Stevens-Johnson syndrome in central China. |
| Q36603317 | Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy |
| Q50102015 | Association of the HLA-B alleles with carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in the Javanese and Sundanese population of Indonesia: the important role of the HLA-B75 serotype. |
| Q36253270 | Bibliometric analysis of literature on toxic epidermal necrolysis and Stevens-Johnson syndrome: 1940 - 2015 |
| Q34598487 | Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. |
| Q47546923 | Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update. |
| Q34345953 | Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing. |
| Q34280685 | Clinical application of pharmacogenomics |
| Q48119431 | Comparison between the HLA-B∗58 : 01 Allele and Single-Nucleotide Polymorphisms in Chromosome 6 for Prediction of Allopurinol-Induced Severe Cutaneous Adverse Reactions. |
| Q28552275 | Comparison of a New In-House and Three Published HLA-B*15:02 Screening Methods for Prevention of Carbamazepine-Induced Severe Drug Reactions |
| Q28749095 | Distributions of HLA-A and -B alleles and haplotypes in the Yi ethnic minority of Yunnan, China: relationship to other populations |
| Q55564369 | Drug Induced Hypersensitivity and the HLA Complex. |
| Q37033603 | Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome |
| Q34701492 | Drug hypersensitivity: pharmacogenetics and clinical syndromes |
| Q26739886 | Drug induced exfoliative dermatitis: state of the art |
| Q52346835 | Drug-Induced Skin Adverse Reactions: The Role of Pharmacogenomics in Their Prevention. |
| Q38667195 | Early toxic epidermal necrolysis syndrome post-intra-cranial tumor resection |
| Q34976470 | Epidemiology and risk factors for drug allergy |
| Q84289446 | Epilepsy: HLA alleles linked to carbamazepine hypersensitivity |
| Q42530312 | Ethnicity and adverse drug reactions |
| Q33926313 | Expectations, validity, and reality in pharmacogenetics |
| Q39261119 | External quality assessment for laboratory testing of HLA-B*15:02 allele in relation to carbamazepine therapy. |
| Q43207061 | GSTT1 and GSTM1 null mutations and adverse reactions induced by antituberculosis drugs in Koreans |
| Q40290352 | Genetic and immune predictors for hypersensitivity syndrome to antiepileptic drugs |
| Q89155792 | Genetic markers of severe cutaneous adverse reactions |
| Q47244043 | Genetic variation in CFH predicts phenytoin-induced maculopapular exanthema in European-descent patients |
| Q38207944 | Genetics of immune-mediated adverse drug reactions: a comprehensive and clinical review |
| Q28943413 | Genome-wide association study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Europe |
| Q34257932 | Genome-wide mapping for clinically relevant predictors of lamotrigine- and phenytoin-induced hypersensitivity reactions |
| Q38292930 | Genomic architecture of pharmacological efficacy and adverse events |
| Q38058271 | HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review |
| Q37341208 | HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children. |
| Q34172669 | HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans |
| Q51352373 | HLA-B*1502 allele is associated with a cross-reactivity pattern of cutaneous adverse reactions to antiepileptic drugs. |
| Q35827699 | HapMap, pharmacogenomics, and the goal of personalized prescribing |
| Q92436059 | Human leukocyte antigen-associated severe cutaneous adverse drug reactions: from bedside to bench and beyond |
| Q37755833 | Ibuprofen-induced hypersensitivity syndrome |
| Q39013940 | Identification of Stevens-Johnson syndrome and toxic epidermal necrolysis in electronic health record databases |
| Q26824391 | Idiosyncratic adverse drug reactions: current concepts |
| Q46819272 | Ketamine continuous infusion for refractory status epilepticus in a patient with anticonvulsant hypersensitivity syndrome |
| Q26800976 | New genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivity |
| Q43160887 | New insights in toxic epidermal necrolysis (Lyell's syndrome): clinical considerations, pathobiology and targeted treatments revisited |
| Q83690300 | Oral hairy leukoplakia in a patient on long-term anticonvulsant treatment with lamotrigine |
| Q37472027 | Patch testing for the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic review |
| Q42157342 | PharmGKB summary: carbamazepine pathway |
| Q35168561 | PharmGKB summary: very important pharmacogene information for human leukocyte antigen B. |
| Q34118186 | Pharmacogenetics of drug hypersensitivity |
| Q34965532 | Pharmacogenetics: from discovery to patient care |
| Q34342305 | Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury |
| Q88472697 | Pharmacokinetic Interaction Between Fingolimod and Carbamazepine in Healthy Subjects |
| Q37742068 | Pharmacotherapy of bipolar disorder in children and adolescents: recent progress |
| Q37874437 | Phenotype standardization for immune-mediated drug-induced skin injury. |
| Q47566249 | Precision medicine: does ethnicity information complement genotype-based prescribing decisions? |
| Q39729427 | Prevention of severe cutaneous adverse drug reactions: the emerging value of pharmacogenetic screening |
| Q34280673 | Problems with the collection and interpretation of Asian-American health data: omission, aggregation, and extrapolation |
| Q38931289 | Recent advances in the understanding of severe cutaneous adverse reactions |
| Q40843603 | Research on Susceptible Genes and Immunological Pathogenesis of Cutaneous Adverse Drug Reactions in Chinese Hans |
| Q50115047 | SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation. |
| Q28076600 | Severe Cutaneous Adverse Reactions: The Pharmacogenomics from Research to Clinical Implementation |
| Q37992545 | Severe drug eruptions revisited |
| Q53825089 | Stevens - Johnson Syndrome and Toxic Epidermal Necrolysis; Extensive Review of Reports of Drug-Induced Etiologies, and Possible Therapeutic Modalities. |
| Q41494133 | Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Associations, Outcomes, and Pathobiology-Thirty Years of Progress but Still Much to Be Done |
| Q38164730 | Stevens-Johnson syndrome / toxic epidermal necrolysis: an Asia-Pacific perspective |
| Q37436365 | Successful translation of pharmacogenetics into the clinic: the abacavir example |
| Q36599215 | Systems biology approaches for identifying adverse drug reactions and elucidating their underlying biological mechanisms |
| Q28547386 | The Absence of CYP3A5*3 Is a Protective Factor to Anticonvulsants Hypersensitivity Reactions: A Case-Control Study in Brazilian Subjects |
| Q50094090 | The association of HLA B*15:02 allele and Stevens-Johnson syndrome/toxic epidermal necrolysis induced by aromatic anticonvulsant drugs in a South Indian population. |
| Q38200683 | The emerging era of pharmacogenomics: current successes, future potential, and challenges |
| Q37859622 | The genetics of antiepileptic drug-induced skin reactions |
| Q40619738 | The p-i Concept: Pharmacological Interaction of Drugs With Immune Receptors |
| Q34016198 | The risk of cutaneous adverse reactions among patients with the HLA-A* 31:01 allele who are given carbamazepine, oxcarbazepine or eslicarbazepine: a perspective review |
| Q21202877 | Toxic epidermal necrolysis and Stevens-Johnson syndrome |
| Q93604507 | Toxic epidermal necrolysis: an update |
| Q36729620 | Various pharmacogenetic aspects of antiepileptic drug therapy: a review |
| Q30600102 | What are our AIMs? Interdisciplinary Perspectives on the Use of Ancestry Estimation in Disease Research |
| Q54222263 | [Acute life-threatening drug reactions of the skin]. |
| Q87860038 | [Severe drug-induced skin reactions. Stevens-Johnson syndrome and toxic epidermal necrolysis] |
| Q52641233 | [Severe skin reactions due to new medications]. |
Search more.